Composition comprising coated cyclodextrin complexes

A gamma-cyclodextrin-based composition coated with hydroxypropyl starch and phosphatidylcholine enhances the solubility and dissolution of poorly soluble drugs, addressing the limitations of existing cyclodextrin complexation methods and improving bioavailability.

WO2026234089A1PCT designated stage Publication Date: 2026-11-12EVANIUM HEALTHCARE GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063093
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for forming cyclodextrin complexes, particularly with gamma-cyclodextrin, fail to sufficiently enhance the bioavailability of poorly soluble drugs due to the formation of supramolecular aggregates leading to low solubility and poor dissolution behavior.

Method used

A composition comprising an active ingredient complexed with gamma-cyclodextrin, coated with hydroxypropyl starch and phosphatidylcholine, in specific weight fractions, enhances solubility and dissolution by forming a stable coating that allows effective release and absorption.

Benefits of technology

The composition significantly improves the solubility and dissolution of poorly soluble active ingredients, particularly those with low water solubility, facilitating effective oral administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063093_12112026_PF_FP_ABST
    Figure EP2026063093_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a composition comprising at least one cyclodextrin complex, in which at least one active ingredient is associated with gamma-cyclodextrin, wherein the cyclodextrin complex has a coating comprising hydroxypropyl starch and phosphatidylcholine, wherein the proportion by weight of the active ingredient is 5-50 wt%, preferably 10-40 wt%, the proportion by weight of the gamma-cyclodextrin is 35-90 wt%, preferably 50-85 wt%, the proportion by weight of the hydroxypropyl starch is 0.1-10 wt%, preferably 0.5-7.55 wt%, more preferably 0.75-4 wt%, particularly preferably 1-3.5 wt%, and the proportion by weight of the phosphatidylcholine is 0.1-10 wt%, preferably 0.5-7.5 wt%, more preferably 1-4.5 wt%, particularly preferably 1.5-4 wt%, based in each case on the total mass of the coated complex.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Composition with coated cyclodextrin complexes

[0002] The invention relates to a system of coated cyclodextrin complexes loaded with an active ingredient encapsulated in gamma-cyclodextrin. Furthermore, their use for improving bioavailability upon oral administration and a method for producing the coated cyclodextrin complexes are described.

[0003] background

[0004] Active ingredients with low water solubility often result in low bioavailability when taken orally. This low solubility leads to incomplete release during the digestive process and consequently reduced absorption.

[0005] To overcome the problem of low solubility, various techniques have been developed in the field. In this context, the complexation of active pharmaceutical ingredients (APIs) with cyclodextrins, ring-shaped starch molecules, has been described. Here, the API displaces water from the cyclodextrin's cavity and forms an inclusion complex, stabilized by non-covalent bonds between the glucose molecules of the cyclodextrin and the sparingly soluble API. Common cyclodextrins include alpha-cyclodextrin (6 glucose molecules), beta-cyclodextrin (7 glucose molecules), and gamma-cyclodextrin (8 glucose molecules). Various methods for complex formation are described in the literature, whereby the API and cyclodextrin form the inclusion complex under stirring—sometimes under the influence of shear forces, temperature increases, or pH fluctuations.This reaction is described by the complex formation constant Ks, which depends in particular on the structure of the active ingredient, its polarity, solubility, and interaction with the cyclodextrin. Common manufacturing processes aim to increase the yield while simultaneously saving time, with the final cyclodextrin complex being fundamentally similar or identical in its properties.

[0006] The literature also describes how complexes with native cyclodextrins, and especially those with gamma-cyclodextrin, exhibit low solubility despite sometimes high complex formation constants and favorable complex geometry. This is due to the formation of supramolecular aggregates, which can form a crystal lattice and undergo stacking. This leads to low solubility and poor dissolution behavior of gamma-cyclodextrin complexes, even when using high-yield preparation methods with effective complex formation. For this reason, gamma-cyclodextrin has been used less frequently than other cyclodextrins in this field for the purpose of improving solubility.

[0007] Conventional methods of complex formation with cyclodextrins often fail to sufficiently improve the bioavailability of orally administered drugs. The object of the invention was therefore to develop a method for further improving the bioavailability of poorly soluble drugs.

[0008] Description

[0009] Surprisingly, it has now been found that by combining preferably low-viscosity hydroxypropyl starch with phospholipids in a specific ratio and concentration, as well as using special processes, gamma-cyclodextrin complexes with significantly higher solubility and dissolution compared to native complexes can be produced.

[0010] A first aspect of the invention therefore relates to a composition comprising an active ingredient complexed with gamma-cyclodextrin, wherein the complex has a coating comprising hydroxypropyl starch and phosphatidylcholine.

[0011] A composition according to the invention comprises at least one cyclodextrin complex, wherein at least one active ingredient is associated with gamma-cyclodextrin, the cyclodextrin complex having a coating comprising hydroxypropyl starch and phosphatidylcholine.

[0012] wherein the weight fraction of the active ingredient is 5-50 wt.%, preferably 10-40 wt.%, the weight fraction of the gamma-cyclodextrin is 35-90 wt.%, preferably 50-85 wt.%,

[0013] the weight fraction of hydroxypropyl starch is 0.1-10 wt.%, preferably 0.5-7.5 wt.%, more preferably 0.75-4 wt.%, particularly preferably 1-3.5 wt.%, and

[0014] The weight fraction of phosphatidylcholine is 0.1-10 wt.%, preferably 0.5-7.5 wt.%, more preferably 1-4.5 wt.%, particularly preferably 1.5-4 wt.%.

[0015] Each value is based on the total mass of the coated complex. The composition is preferably in solid form, as the coated cyclodextrin complexes then exhibit particularly good stability. Alternatively, the composition can also be in aqueous solution; for example, it can be dissolved directly before desired use.

[0016] For the purposes of the invention, sparingly soluble active ingredients are those with a solubility of up to 10 mg / ml in pure water at 20°C:

[0017] Solubility classification: Absolute solubility (distilled water, 20°C) Very Soluble >1000mg / ml

[0018] Freely Soluble 100-1000mg / ml

[0019] Soluble 33-100mg / ml

[0020] Sparingly Soluble 10-33mg / ml

[0021] Slightly Soluble 1-10mg / ml

[0022] Very Slightly Soluble 0.1-1mg / ml

[0023] Practically Insoluble <0.1mg / ml

[0024]

[0025] For corresponding active ingredients in the category "Practically Insoluble" and "Very Slightly Soluble", and in a broader sense also "Slightly Soluble", effective administration via oral dosage is problematic.

[0026] Surprisingly, it was found that the corresponding active ingredients dissolve or are released very effectively when formulated in the form of a gamma-cyclodextrin complex, which is additionally coated with hydroxypropyl starch and phospholipids.

[0027] Phospholipids, modified starch, and cyclodextrins are all frequently used to increase solubility. While phospholipids are often used to form liposomal structures, modified starches act as micelle formers, and cyclodextrins as complexing agents. However, the mechanisms of solubility enhancement are additive at best, but in most cases antagonistic, since in practice the active ingredient competes with the phospholipids or the functional groups of the modified starch for complex formation. Surprisingly, it has been found that a specific concentration ratio, combined with a final coating process, enables significantly super-additive solubility. The key component here, besides the selection of gamma-cyclodextrin, is the final coating, for which hydroxypropyl-modified starch and phosphatidylcholine are used.

[0028] The weight fraction of gamma-cyclodextrin is 35–90 wt.%, based on the total mass of the coated complex. A content in the range of 50–85 wt.% gamma-cyclodextrin is particularly advantageous. For other cyclodextrin types, such as alpha- or beta-cyclodextrin, no superadditive increase in solubility can be achieved through the inventive process or composition.

[0029] Phosphatidylcholine, optionally in combination with other phospholipids, serves according to the invention, together with hydroxypropyl starch, to coat the gamma-cyclodextrin complex and to interact with gamma-cyclodextrin, thereby significantly increasing the solubility.

[0030] Phospholipids are a group of lipid molecules that play a central role in biological membranes. They consist of fatty acids, a glycerol molecule, a phosphate group, and a polarized head, which is often linked to an additional chemical group (e.g., choline, ethanolamine, serine). For the purposes of the invention, purified phospholipids with a phosphatidylcholine content of at least 40%, preferably > 70%, particularly preferably > 80%, and most preferably > 90%, can be used. The amount of phospholipids is selected such that the proportion of phosphatidylcholine (PC) in the complex coating, based on the total mass of the coated complex, is approximately 0.1–10 wt%, preferably 0.5–7.5 wt%. Particularly advantageous are proportions in the range of 1-4.5 wt.%, preferably 1.5-4 wt.% phosphatidylcholine based on the total mass of the coated complex.

[0031] Highly purified phospholipids, and in particular phosphatidylcholine relevant to the invention, are mainly produced from plant or animal sources, especially soybeans, sunflower seeds, or egg yolks. The process comprises several steps, including extraction, purification, and fractionation, to achieve the desired degree of purity. First, the starting materials are extracted using a nonpolar solvent such as hexane, or the fat-rich fraction is obtained by mechanical pressing and then refined. Subsequently, crude lecithin is obtained by de-oiling (e.g., by water hydration or acetone treatment). This lecithin is a mixture of various phospholipids, in particular phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and sphinomyelin. By fractionation or...Purification involves purifying the components, either by enzymatic cleavage of unwanted phospholipids by phospholipases and / or by chromatographic separation using adsorption chromatography with a suitable solvent such as ethanol or acetone. Extraction using supercritical CO2 is also possible.

[0032] Particularly relevant for the classification of a phospholipid is:

[0033] 1. The proportion of phosphatidylcholine (PC) relative to the total phospholipids and expressed in wt%

[0034] 2. The proportion of other phospholipids, in particular PS, PE, PI, relative to the total phospholipids and expressed in wt.%

[0035] For the purposes of the invention, preferably pure phosphatidylcholine or purified phospholipids with a PC content of at least 40%, preferably >70%, particularly preferably >85%, and ideally >90%, are used. Besides PC, other phospholipids are also capable of being incorporated into the coating of a cyclodextrin complex according to the invention. Therefore, the coating can also comprise one or more additional phospholipids besides PC.

[0036] Modified starch is used exclusively in the form of hydroxypropyl starch. According to the invention, hydroxypropyl starch refers in particular to starch ether derivatives in which the hydroxyl groups of the glucose unit of the starch are etherified with propylene oxide. The weight fraction of hydroxypropyl starch in the complex coating is 0.1–10 wt.%, preferably 0.5–7.5 wt.%, based on the total mass of the coated complex. Particularly advantageous are proportions in the range of 0.75–4 wt.%, preferably 1–3.5 wt.% of hydroxypropyl starch based on the total mass of the coated complex.

[0037] Essential factors in selecting a suitable hydroxypropyl starch are, firstly, its degree of substitution and, secondly, its viscosity. The degree of substitution, expressed as a weight percent of the modified unit (= mass fraction of the substituent groups in the total mass), refers to the dry mass and can be determined by nuclear magnetic resonance spectroscopy (e.g., described in Ph. Eur. 11.0 Determination of the content of Amylum hydroxypropylum pregeleficatum). Starch used according to the invention preferably has a degree of substitution of 0.1–15%, more preferably 0.5–10%, and most preferably 2–7%. The viscosity of the modified starch can be measured by rotational viscometry. The rotational viscometry method is explained in the standard ISO 1652:2011 Rubber latex – Determination of apparent viscosity by the Brookfield test method. For example, the measurement can be carried out using a Brookfield LV viscometer, spindle LV1 as 10 wt.The viscosity of the starch is measured in a 10 wt% solution at 25°C. According to the invention, starches with a viscosity of at most 1800 mPas are preferably used, with lower viscosities being preferred. Advantageously, the viscosity of the starch used is < 500 mPas or < 250 mPas, preferably < 100 mPas, particularly preferably < 75 mPas, and ideally < 50 mPas, as measured by rotational viscometry, especially according to ISO 1652:2011 at 25°C as a 10 wt% solution. Hydroxypropyl starches with a viscosity in this range are particularly well suited to achieving a uniform coating that also does not impair the stability of the formulation. With higher viscous starches, on the other hand, the coating is so pronounced that it leads to instability of the formulation.

[0038] Suitable starches for the use according to the invention can be obtained by treating starch with propylene oxide after gelatinization and shortening of the chain lengths by enzymatic treatment or dextrinization (fluidization), resulting in the structure shown in Fig. 1 (hydroxypropyl starch).

[0039] Relevant for the classification of strengths are, in particular,

[0040] 1. Degree of substitution, expressed as a weight percent of the modified unit, based on the dry mass, determined by NMR.

[0041] 2. Viscosity of the starch, as required by the invention, measured by rotational viscometry, for example with a Brookfield LV viscometer, spindle LV1 as a 10 wt% solution at 25°C

[0042] For the purposes of the invention, starches with a viscosity of at most 1800 mPas are preferably used. Starches with a low viscosity (< 500, preferably < 250 mPas, more preferably < 100 mPas, particularly preferably < 75 mPas, best < 50 mPas in a 10 wt% w / w solution at 25°C) are advantageous. The degree of substitution of the starch used is preferably 0.1–15%, more preferably 0.5–10%, and particularly preferably 2–7% hydroxypropyl groups based on the dry mass (measured according to ISO 1652:2011 at 25°C as a 10 wt% solution).

[0043] The combined weight fraction of phosphatidylcholine and hydroxypropyl starch in the complex coating is advantageously 0.5–15 wt.%, preferably 1–10 wt.%, more preferably 1.5–8.5 wt.%, and particularly preferably 2–7 wt.%, based on the total mass of the coated complex. Furthermore, it is possible that a composition according to the invention may comprise additional amounts of starch and phosphatidylcholine that are not part of the coating of the cyclodextrin complex.

[0044] In a composition according to the invention, the coated cyclodextrin complexes are present, in particular, in the form of agglomerates of several individual complexes. Due to the coating according to the invention, these agglomerates dissolve particularly easily again (into smaller agglomerates or, in particular, individual coated cyclodextrin complexes) when the composition is dissolved or, for example, administered orally.

[0045] The particle size of the individual coated cyclodextrin complex particles in solution is approximately 0.1-10 pm, preferably 0.2-5 pm, particularly preferably 0.3-4 pm, expressed as a D50 value, which is measured by laser diffraction, for example with a Mastersizer 3000 from Malvern Panalytical.

[0046] In preferred embodiments of the invention, the composition further comprises one or more carrier substances or lyoprotectors. According to the invention, these are compounds that are water-soluble and capable of forming hydrogen bonds with the coated cyclodextrin complexes. During the drying process, they replace the water molecules and stabilize the coated complexes by forming hydrogen bonds. Particularly preferred carrier substances or lyoprotectors are saccharides, especially in the form of maltodextrin. These can be selected from the group consisting of maltodextrin, glucose, sucrose, fructose, maltose, lactose, galactose, trehalose, mannose, and combinations thereof. The use of starch hydrolysates with a dextrose equivalent (DE) of 3-50 is preferred, particularly preferably with a DE of 5-30, and ideally with 10-20. The weight fraction of the carrier substances or lyoprotectors is determined by the specific composition.Lyoprotectants, in particular saccharides, can amount to a total of 5-50 wt.%, preferably 10-40 wt.%, preferably 12.5-35 wt.%, and particularly preferably 15-30 wt.%, based on the total mass of the coated complex.

[0047] Active ingredients that can be encapsulated in the coated cyclodextrin complexes according to the invention are, in particular, hydrophobic active ingredients with a low water solubility of 10 mg / ml and less (in pure water at 20°C). The encapsulation according to the invention is particularly advantageous for active ingredients with a water solubility of < 1 mg / ml. The molecular weight of the active ingredients can be in the range of 150–2000 g / mol. The chemical structure of the active ingredients is, in principle, freely selectable, provided they are capable of non-covalent interaction with gamma-cyclodextrin. They can be natural or synthetic substances with low water solubility.

[0048] Preferred are primarily poorly soluble secondary plant metabolites and their glycosides such as stilbenoids (resveratrol, pterostilbene, piceatannol, rhaponticin, deoxyrhaponticin, gnetin), flavonoids, especially flavonols (fisetin, quercetin, kaempferol, rutin, myricetin, isorhamnetin), flavanones (naringenin, hesperitin), flavanols (catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavins), isoflavones (genistein, daidzein, glytetein), anthocyanidins / anthocyanins (cyanidin, delphinidin, malvidin), dihydroflavonols (taxifolin, dihydrokaempferol, dihydromyricetin), neoflavonoids (pterocarpan, coumestrol), and flavonolignans. (Silibinin, Isosilybin, Silychristin, Silydianin), Flavones (Apigenin, Luteolin, Baicalein, Chrysin, Tangeretin), C-Glycosylflavones (Isovitexin, Vitexin), Monoterpenes (Thujone, Limonene, Menthol, Carvone, Cineole, Pinene, Linalool), Diterpenes (Ginkgolide, Carnosol, Carnosolic acid, forskolin), sesquiterpenes (beta-caryophyllene), triterpenes (lupeol,Ursolic acid, betulinic acid, beta-boswellic acid, alpha-boswellic acid, 11-keto-beta-boswellic acid, 3-O-acetyl-11-keto-beta-boswellic acid), chalcones (xanthohumol, phloretin, butein, flavokavain, hesperetin or naringenin chalcone), curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin), lignans (secoisolariciresinol, matairesinol, enterolactone), hydroquinone derivatives (thymoquinone), cinnamic acid derivatives (ferulic acid, coumaric acid, chlorogenic acid, rosmarinic acid), gingerols ([6]-gingerol, [8]-gingerol,

[0010] -gingerol), shogaols ([6]-shogaol, [8]-Shogaol,

[0010] -Shogaol), (steroids (beta-sitosterol, campesterol, stigmasterol, gamma-oryzanol), xanthones (mangostine, norathyriol) and anthraquinones (emodin, aloe-emodin, rhine), carotenoids (ß-carotene, lutein, zeaxanthin, lycopene, astaxanthin), alkaloids (berberine, capsaicin, caffeine, theobromine, piperine), saponins (ginsenosides), tocopherols (alpha-, beta-, gamma-, delta-tocopherol), tocotrienols (alpha-, beta-, gamma-,delta-tocotrienol), glucosinolates (sulforaphane).,

[0049] In addition, the application is also preferred for other poorly soluble substances such as alpha-lipoic acid, ubiquinone, ubiquinol, melatonin, menadione, menaquinone, phylloquinone, cholecalciferol, ergocalciferol, 22-dihydroergocalciferol, sitocalciferol, dehydroepiandrosterone, glutathione, omega-3 fatty acids and their esters (alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid).

[0050] Furthermore, its use is particularly favored for poorly soluble pharmaceutical agents such as antibiotics (amoxicillin, ciprofloxacin, azithromycin, tetracycline), analgesics (ibuprofen, diclofenac, ketoprofen, naproxen), antidiabetics (metformin, glibenclamide, pioglitazone, glimepiride), antihypertensives (losartan, atenolol, hydrochlorothiazide, verapamil), antidepressants (amitriptyline, fluoxetine, sertraline, paroxetine), antiemetics (ondansetron, metoclopramide, domperidone, prochlorperazine), anticoagulants (warfarin, dabigatran, apixaban), antifungals (itraconazole, ketoconazole, fluconazole, terbinafine), antivirals (acyclovir, oseltamivir, lamivudine), and antitumor agents. (paclitaxel, doxorubicin, docetaxel, vincristine), neuroleptics (haloperidol, olanzapine, quetiapine, clozapine), sedatives and hypnotics (diazepam, lorazepam, midazolam, clonazepam), lipid regulators (atorvastatin, simvastatin, lovastatin, pravastatin), immunosuppressants (cyclosporine A, tacrolimus, mycophenolate mofetil),Anticonvulsants (phenytoin, carbamazepine, valproic acid, lamotrigine), proton pump inhibitors (omeprazole, lansoprazole, pantoprazole), corticosteroids (prednisone, dexamethasone, hydrocortisone), vitamin D analogues (calcipotriol, paricalcitol, tacalcitol), analgesic opioids (morphine, oxycodone, fentanyl, buprenorphine), retinoids (isotretinoin, tretinoin).

[0051] The weight fraction of the active ingredient in the total mass of the coated complex is 5-50 wt.%. Active ingredient loadings in the range of 10-40 wt.% of the active ingredient, based on the total mass of the coated complex, are particularly advantageous.

[0052] The combined weight fraction of the active ingredient + gamma-cyclodextrin in the total mass of the coated complex is preferably between 85-99 wt.%, preferably 90-98.5 wt.%, particularly preferably about 93-98 wt.%.

[0053] The composition according to the invention is particularly well suited for oral administration due to its improved solubility and dissolution. It can be available, for example, in the form of a tablet, capsule, chewable, orodispersible or effervescent tablet, as granules, as a powder, in solution for oral administration, as a coated tablet, as a sublingual / buccal tablet, or as an orodispersible film.

[0054] In addition to the coated cyclodextrin complexes, a composition according to the invention may comprise other usual components of a formulation intended for oral administration.

[0055] The composition according to the invention can be formulated as a pharmaceutical or nutraceutical composition, as well as a foodstuff. In a preferred embodiment, the composition according to the invention is intended for nutraceutical use. Depending on the desired use of the coated cyclodextrin complexes, they can be further processed into a composition for oral administration. For this purpose, the composition can be formulated, for example, as a tablet, capsule, chewable, orally disintegrating or effervescent tablet, as granules, as a powder, as a solution for oral administration, as a coated tablet, as a sublingual / buccal tablet, or as a melt-in-the-mouth film, and optionally combined with other ingredients.

[0056] Another aspect of the invention relates to a method for producing a composition described above, comprising coated cyclodextrin complexes, wherein the method comprises the following steps:

[0057] a) Dispersing gamma-cyclodextrin and at least one active ingredient in water while stirring to associate the active ingredient with the gamma-cyclodextrin, b) Coating the cyclodextrin complex formed in step (a) by adding hydroxypropyl starch and phosphatidylcholine while stirring and homogenizing to obtain a suspension of coated cyclodextrin complexes in water, and c) optionally drying the suspension obtained in step (b).

[0058] In step a) of the preparation of an aqueous dispersion, the active ingredient is associated with the gamma-cyclodextrin. For this purpose, an aqueous solution of the gamma-cyclodextrin can be used, followed by the addition of the active ingredient. The dispersion is preferably carried out with stirring, for example in a high-shear homogenizer.

[0059] For the purposes of the invention, association is understood to mean a non-covalent interaction of the active ingredient with the gamma-cyclodextrin, wherein the active ingredient can be wholly or partially incorporated into the cavity of the gamma-cyclodextrin, so that an inclusion complex is formed in which the active ingredient is embedded in the gamma-cyclodextrin. The complexation of the active ingredient with gamma-cyclodextrin can be promoted by adjusting the pH value.

[0060] The weight ratio of gamma-cyclodextrin and active ingredient is selected such that the active ingredient is absorbed into the cyclodextrin as completely as possible. Advantageously, the weight fraction of the active ingredient is approximately 5–50 wt% and the weight fraction of the gamma-cyclodextrin is approximately 35–90 wt%, each based on the total mass of the coated complex. Preferred weight fractions are described above in connection with a composition according to the invention. In the subsequent step b), hydroxypropyl starch and phosphatidylcholine are added to the dispersion obtained in step a), and homogenization takes place. This causes the hydroxypropyl starch and phosphatidylcholine to arrange themselves in the aqueous dispersion to form a shell around the cyclodextrin complex, which encloses the active ingredient associated with gamma-cyclodextrin.Homogenization can be achieved by means of high-pressure homogenization, ultrasonic homogenization or grinding, for example in a ball mill.

[0061] In the case of high-pressure homogenization, the coating is applied, for example, by passage at low to medium pressure (100–800 bar), typically requiring 1–5 cycles. For homogenization using a ball mill, grinding media with diameters of 0.05–1 mm, preferably 0.1–0.8 mm, and particularly preferably 0.3–0.4 mm, are preferably selected. These media are made of stainless steel, glass, zirconium oxide, tungsten carbide, aluminum oxide, PTFE, or agate; grinding media made of zirconium oxide are particularly preferred. For homogenization by ultrasound, either sonotrodes, ultrasonic baths, or flow-through ultrasonic homogenizers / ultrasonic chambers can be used.

[0062] The amount of phosphatidylcholine is preferably selected such that its weight fraction in the coating, based on the total mass of the coated complex, is approximately 0.1–10 wt.%, preferably 0.5–7.5 wt.%. Weight fractions of 1–4.5 wt.% or 1.5–4 wt.% of phosphatidylcholine, based on the total mass of the coated complex, are particularly suitable. According to the invention, phosphatidylcholine (PC) can be used in the form of a mixture of phospholipids. Purified phospholipids with a PC content of at least 40%, preferably > 70%, particularly preferably > 80%, and ideally > 90%, can be used.

[0063] The amount of hydroxypropyl starch used is selected such that a weight fraction in the coating of approximately 0.1–10 wt.%, preferably 0.5–7.5 wt.%, more preferably 0.75–4 wt.%, and particularly preferably 1–3.5 wt.%, is achieved, based on the total mass of the coated complex. These amounts are optimal for the coating.

[0064] Suitable hydroxypropyl starches for use in the process according to the invention are the starches described above in connection with a composition.

[0065] To promote the coating of the cyclodextrin complexes, the pH value can be adjusted accordingly. In preferred embodiments of the invention, one or more carrier substances or lyoprotectors such as saccharides, particularly in the form of maltodextrin, are added to the suspension of coated (and optionally homogenized) cyclodextrin complexes. These facilitate the drying of the coated cyclodextrin complexes and improve their stability. Saccharides can be selected from the group comprising maltodextrin, glucose, sucrose, fructose, maltose, lactose, galactose, trehalose, mannose, and combinations thereof. The use of starch hydrolysates with a dextrose equivalent (DE) of 3–50 is preferred, particularly preferably with a DE of 5–30, and ideally with 10–20. The weight fraction of the carrier materials or lyoprotectors, especially the saccharides, can amount to an additional 5-50 wt. in relation to the total mass of the coated complex.-%, preferably 10-40 wt.%, preferably 12.5-35%, particularly preferably 15-30 wt.%.

[0066] In step (c) the suspension obtained in step (b) is finally dried, for example by spray drying, freeze-drying, vacuum belt drying or spray granulation.

[0067] Depending on the intended use of the coated cyclodextrin complexes, they can be further processed into a composition for oral administration. For this purpose, the composition can be formulated, for example, as a tablet, capsule, chewable, orally disintegrating or effervescent tablet, as granules, as a powder, in solution for oral administration, as a coated tablet, as a sublingual / buccal tablet, or as a melt-in-the-mouth film.

[0068] The following examples and figures are intended to further illustrate the invention. However, the invention is not limited to these specific examples, but extends to the entire scope of the claims.

[0069] Figures

[0070] Fig. 1 Reaction scheme of the derivatization of starch with propylene oxide

[0071] Examples

[0072] To determine the optimal formulation for bioavailability, solubility, and dissolution, various modified starches were first characterized with respect to viscosity, and formulations containing the sparingly soluble active ingredients curcumin, quercetin, boswellic acids, berberine, and silibinin were prepared. Following subsequent characterization, the saturation solubility and release in various media were determined. The concentration values ​​in the examples refer to the total composition.

[0073] 1. Characterization of strengths (viscosity)

[0074] Various modified starches (acetyl [E1420], sodium octenyl succinate [E1450], and hydroxypropyl starches [E1440], as well as hydroxypropyl distarch phosphate [E1442]) were investigated for viscosity. For this purpose, the dried starches were dissolved on a magnetic stirrer (20 g starch + 180 ml distilled water) to prepare a 10 wt% solution. This solution was then measured using a Brookfield DVPIus viscometer (DVPLLV) at 25°C.

[0075] 10 wt% sodium octenylsuccinate starches (E1450, OSA starch):

[0076] Strength / Commercial Name Abbreviation Viscosity at Spindle

[0077] 25°C [mPas]

[0078] Hi-Caps 100 (Ingredion) HC100 2-5 Spindle LV-1 Cleargum CO03 (Roquette) CO03 3-8 Spindle LV-1

[0079] Purity Gum Ultra (Ingredion) PGU 50-75 Spindle LV-1

[0080] N-Creamer 2230 (Ingredion) NC2230 8,000 - 15,000 Spindle LV-3

[0081]

[0082] 10 wt% hydroxypropyl starches (E1440, HP starch):

[0083] Strength / Commercial Name Abbreviation Viscosity at Spindle

[0084] 25°C [mPas]

[0085] Lycoat RS 780 (Roquette) RS780 8-13 Spindle LV-1

[0086] Lycoat RS 720 (Roquette) RS720 25-50 Spindle LV-1

[0087] HPS-T301 (WOTAI brazen) T301 600-1,800 Spindle LV-2 FloTexa-TS-57900 (Angel FTTS 2,200-5,400 Spindle LV-3

[0088] Starch)

[0089]

[0090] 10 wt% hydroxypropyl distarch phosphate (E1442 HDP starch):

[0091] Strength / Commercial Name Abbreviation Viscosity at Spindle

[0092] 25°C [mPas]

[0093] Purity 87 (Ingredion) P87 400-1300 Spindle LV-2

[0094] Prejel VA 70 (Avebe) PVA70 6,500-12,000 Spindle LV-3

[0095]

[0096] 10 wt. -% acetyl starches (E1420, AS starch):

[0097] Strength / Commercial Name Abbreviation Viscosity at Spindle

[0098]

[0099] 25°C [mPas]FROSIN TM-MS-CWS FTM 40-160 Spindle LV-1 (Angel Starch)

[0100] FROSIN-PS (Angel Starch) FPS 1,800-5,000 Spindle LV-3

[0101]

[0102] 2. Active ingredient formulations containing curcumin

[0103] Ingredients: Curcumin (98%, Thermo Fisher Scientific), alpha-cyclodextrin (CAVAMAX W6, Wacker Chemie), beta-cyclodextrin (CAVAMAX W7, Wacker Chemie), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (96%, LIPOID H100, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), NaOH (grade according to Ph.Eur., generic), HCl (fuming 32%, generic), modified starches (see 1. Characterization of starches)

[0104] 2.1 Influence of the modified strength

[0105] Powdered curcumin complexes with the following final composition were produced to estimate the optimal starch type:

[0106] Component by weight [wt.%]

[0107] Curcumin 10

[0108] Gamma-cyclodextrin 70

[0109] Phosphatidylcholine 2.5

[0110] Modified strength 2.5

[0111] Maltodextrin 15

[0112]

[0113] First, 70 g of gamma-cyclodextrin (CAVAMAX W8) and 10 g of curcumin were dispersed in 900 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 5000 rpm and then adjusted to a pH of 10–11 with NaOH. To initiate complex formation, the suspension was dispersed for a further 30 min at 5000 rpm, and the pH was subsequently neutralized by adding HCl solution while stirring gently (final pH 4.5). Following this, 2.5 g of modified starch (HC100, CO03, PGU, NC2230, RS780, RS720, T301, FTTS, P87, PVA70, FTM, or FPS) and 2.5 g of phosphatidylcholine (Lipoid H100) were homogeneously dispersed while stirring.

[0114] The suspensions were then milled for 20 minutes in a ball mill (WAB, DYNO-MILL Research Lab, 65% filling with 0.3-0.4 mm zirconia beads, 6 m / s tip speed) using a circular motion and subsequently weighed. Then, 15 g of maltodextrin (GLUCIDEX 19) – corrected for the yield (yield in g / theoretical yield in g x 15 g) – was weighed out and dissolved in the milled suspension by stirring.

[0115] The suspensions were last dried using a laboratory spray dryer (Büchi B-290, 5ml / min flow, inlet temperature 130°C, 800l / h spray gas, 35 m3 / h aspirator).

[0116] For reference, a native gamma-cyclodextrin / curcumin complex (native GCD) was also prepared, initially following the same procedure: 70 g of gamma-cyclodextrin (CAVAMAX W8) and 10 g of curcumin were dispersed in 900 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 5000 rpm and subsequently adjusted to a pH of 10.7 with NaOH. To achieve complex formation, the suspension was dispersed for a further 30 min at 5000 rpm, and the pH of the suspension was then neutralized by adding HCl solution with gentle stirring (final pH 4.8) and subsequently dried using a spray dryer with the same spray parameters.

[0117] The powdered complexes were characterized with respect to total yield, loss on drying (halogen dryer), particle size in solution (D50 value, laser diffraction) and curcumin content (HPLC).

[0118] To measure the particle size in solution, a Mastersizer 3000 (Malvern Panalytical) with a Hydro MV wet dispersion element was used. For this purpose, 20 mg of precisely weighed sample was dispersed in 120 ml of water with a drop of Igepal solution for 10 minutes using gentle ultrasound to separate the particles, which were then measured (evaluation using Mie theory).

[0119] Complex Starch Type Used Yield Drying Curcumin D50 Starch [g] Loss [%] Content Value [wt.%] [pm] CC1A OSA HC100 58.4 4.8 10.2 2.719 CC1B OSA CO03 73.7 4.5 10.0 4.721 CC1C OSA PGU 64.6 5.3 9.7 3.219 CC1D OSA NC2230 34.7 6.5 10.1 12.892 CC2A HP RS780 70.6 5.7 10.1 1.163 CC2B HP RS720 69.8 5.2 10.0 1.340 CC2C HP T301 65.2 6.2 9.9 6.621 CC2D HP FTTS 25.3 77 10.2 6.821

[0120]

[0121] CC3A HDP P87 61.5 6.6 9.7 8.941 CC3B HDP PVA70 28.5 7.8 10.0 15.997 CC4A AS FTM 55.7 7.2 10.1 7.893 CC4B AS FPS 47.8 6.8 9.9 21.783 Native none none 58.3 6.9 12.3 11.921 GCD

[0122] Curcumin - - - 0.22 98.9 24.6

[0123]

[0124] To measure saturation solubility, samples containing 25 mg of curcumin were precisely weighed and dispersed in 100 ml of biorelevant buffer (FASSIF-V2, biorelevant: pH 6.5, buffer capacity 10 mmol / Δp / L containing 3 mM sodium taurocholate; 0.2 mM lecithin; 19.12 mM maleic acid; 34.8 mM sodium hydroxide; 68.62 mM sodium chloride, corresponding to physiological intestinal fluid in terms of composition, pH, ion strength, and buffer capacity) and then incubated for 2 hours with gentle shaking. The samples were then filtered using a syringe filter, and the curcumin concentration of the filtrate was determined by HPLC. The experiments were performed using triplicates, and the mean values ​​are presented in tabular form. Pure curcumin was included as a control.

[0125] Complex Starch Type Volume Used Saturation Solubility Saturation Solubility Starch FASSIF- Curcumin in Curcumin in V2 [ml] FASSIF-V2 [pg / ml] FASSIF-V2 [%] CC1A OSA HC100 100 64.2 25.68

[0126] CC1B OSA CO03 100 58.9 23.56

[0127] CC1C OSA PGU 100 48.9 19.56

[0128] CC1D OSA NC2230 100 44.6 17.84

[0129] CC2A HP RS780 100 158.2 63.28

[0130] CC2B HP RS720 100 152.8 61.12

[0131] CC2C HP T301 100 83.9 33.56

[0132] CC2D HP FTTS 100 69.3 27.72

[0133] CC3A HDP P87 100 38.4 15.36

[0134] CC3B HDP PVA70 100 32.4 12.96

[0135] CC4A AS FTM 100 41.2 16.48

[0136] CC4B AS FPS 100 35.8 14.32

[0137] Native GCD none none 100 54.6 21.84 Curcumin - - 100 1.23 0.492

[0138]

[0139] Subsequently, the in vitro release was investigated according to the specifications of the pharmacopoeia (Ph. Eur. 11.0 Chapter 2.9.3. Release of solid dosage forms). For this purpose, the USP Apparatus II (paddle / leaf stirrer) was selected, the rotation speed was 75 rpm, V = 500 ml Fassif-V2 medium, T = 37°C.

[0140] Samples containing 50 mg of curcumin were precisely weighed, corresponding to a target curcumin concentration of 100 pg / ml. After the medium was brought to the target temperature and the samples were placed in the containers, samples were drawn after 15, 30, 60, and 120 minutes. The samples were filtered using a syringe filter, and the curcuminoid concentration was determined by HPLC. The withdrawn sample volume was immediately replaced with fresh, pre-tempered FASSIF-V2 medium. The experiments were performed using triplicates, and the mean release values ​​(Q in %) are presented in tabular form.

[0141] Complex Strength Type Used Q by Q by Q by Q by Strength 15 min [%] 30 min [%] 60 min [%] 120 min [%] CC1A OSA HC100 40.2 34.46 27.56 20.85 CC1B OSA CO03 31.74 33.17 29.90 24.57 CC1C OSA PGU 35.6 37.5 25.6 18.4 CC1D OSA NC2230 22.3 25.6 28.4 20.8 CC2A HP RS780 72.6 77.4 75.9 65.1 CC2B HP RS720 69.2 74.5 68.7 59.7 CC2C HP T301 50.6 61.2 45.1 36.8 CC2D HP FTTS 32.1 36.7 28.9 25.6 CC3A HDP P87 16.7 21.3 18.5 13.8 CC3B HDP PVA70 9.6 15.6 16.9 10.7 CC4A AS FTM 26.8 32.4 23.5 18.3 CC4B AS FPS 18.7 22.3 16.7 11.2 Native GCD none none 39.4 41.5 32.6 18.4 Curcumin - - 0.11 0.16 0.25 0.46

[0142]

[0143] Only hydroxypropyl starch, and especially low-viscosity hydroxypropyl starch, in combination with phosphatidylcholine achieves a significant increase in saturation solubility and release compared to a native gamma-cyclodextrin / curcumin complex.

[0144] 2.2 Influence of the Cyclodextrin TypeTo investigate the influence of the cyclodextrin type, complexes were prepared according to the procedure from 2.1. with the best modified starch (Lycoat RS780), which, however, contained alpha- or beta-cyclodextrin instead of gamma-cyclodextrin.

[0145] Composition with alpha-cyclodextrin (CC5A):

[0146] Component by weight [wt.%]

[0147] Curcumin 10

[0148] Alpha-Cyclodextrin 70

[0149] Phosphatidylcholine 2.5

[0150] Modified strength (Lycoat RS780) 2.5

[0151] Maltodextrin 15

[0152]

[0153] Composition with beta-cyclodextrin (CC6A):

[0154] Component by weight [wt.%]

[0155] Curcumin 10

[0156] Beta-cyclodextrin 70

[0157] Phosphatidylcholine 2.5

[0158] Modified strength (Lycoat RS780) 2.5

[0159] Maltodextrin 15

[0160]

[0161] For reference, native alpha / beta-cyclodextrin:curcumin complexes (native ACD and native BCD) were also prepared, initially following the same procedure: 70 g of alpha-cyclodextrin (CAVAMAX W6) or 70 g of beta-cyclodextrin (CAVAMAX W7) and 10 g of curcumin were dispersed in 900 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 5000 rpm and then adjusted to a pH of 10–11 with NaOH. For complex formation, the suspension was dispersed for a further 30 min at 5000 rpm, and the pH of the suspension was then neutralized by adding HCl solution with gentle stirring (final pH 4–5) and subsequently dried using a spray dryer with the same spray parameters as described in section 3.2.1.

[0162] These complexes were then tested for saturation solubility and in-vitro release according to the procedure already described.

[0163] To measure saturation solubility, samples containing 25 mg of curcumin were precisely weighed and dispersed in 100 ml of biorelevant buffer (FASSIF-V2, biorelevant: pH 6.5, buffer capacity 10 mmol / Δ pH / L containing 3 mM sodium taurocholate; 0.2 mM lecithin; 19.12 mM maleic acid; 34.8 mM sodium hydroxide; 68.62 mM sodium chloride, corresponding to physiological intestinal fluid in terms of composition, pH, ion strength, and buffer capacity) and then incubated for 2 hours with gentle shaking. The samples were then filtered using a syringe filter, and the curcumin concentration of the filtrate was determined by HPLC. The experiments were performed using triplicates; the average values ​​are presented in tabular form.

[0164] For clarity, the values ​​for the native gamma-cyclodextrin / curcumin complex (native GCD), pure curcumin, and the best complex from 3.2.1. with LycoatRS780 (CC2A) are included in the table:

[0165] Complex CD Used Volume Saturation Solubility Saturation Solubility Strength FASSIF- Curcumin in Curcumin in V2 [ml] FASSIF-V2 [pg / ml] FASSIF-V2 [%] CC5A alpha RS780 100 18.5 7.4

[0166] Native ACD alpha: not 100, 22.3, 8.9

[0167] CC6A beta RS780 100 38.2 15.3

[0168] Native BCD beta no 100 35.5 14.2

[0169] CC2A gamma RS780 100 158.2 63.28

[0170] Native GCD gamma none 100 54.6 21.84 Curcumin - - 100 1.23 0.492

[0171]

[0172] Subsequently, in accordance with the procedure in 3.2.1, the in vitro release was investigated according to the specifications of the pharmacopoeia (Ph. Eur. 11.0 Chapter 2.9.3. Release of solid dosage forms). For this purpose, the USP Apparatus II (paddle / leaf stirrer) was selected, the rotation speed was 75 rpm, V = 500 ml Fassif-V2 medium, T = 37°C.

[0173] Samples containing 50 mg of curcumin were precisely weighed, corresponding to a target curcumin concentration of 100 pg / ml. After the medium was brought to the target temperature and the samples were placed in the containers, sampling was performed after 15, 30, 60, and 120 minutes. The samples were filtered using a syringe filter, and the curcuminoid concentration was determined by HPLC. The withdrawn sample volume was immediately replaced with fresh, pre-tempered FASSIF-V2 medium. The trials were conducted using triplicates; the average release values ​​(Q in %) are shown in tabular form. Complex CD Used Q after Q after Q after Strength 15 min [%] 30 min [%] 60 min [%] 120 min [%] CC5A alpha RS780 5.8 6.3 7.8 7.4 Native ACD alpha none 4.3 5.1 8.9 10.2 CC6A beta RS780 14.3 15.6 16.2 16.1 Native BCD beta none 15.9 16.2 16.3 16.7 CC2A gamma RS780 72.6 77.4 75.9 65.1 Native GCD gamma none 39.4 41.5 32.6 18.4 Curcumin - - 0.11 0.16 0.25 0.46

[0174]

[0175] Only with gamma-cyclodextrin was a significant increase in saturation solubility and dissolution behavior achieved – both relatively compared to the respective native complex and absolutely.

[0176] 2.3 Influence of the proportion of modified starch and phosphatidylcholine

[0177] To determine the influence of the weight fraction of the modified starch and the phosphatidylcholine, complexes were prepared according to the procedure from 2.1. with the best modified starch (Lycoat RS780), phosphatidylcholine (Lipoid H100) and gamma-cyclodextrin, which, however, contained different weight fractions of the two additives.

[0178] In this experiment, either the 2.5% Lycoat RS780 content was maintained and the phosphatidylcholine content was varied (0.1%, 0.5%, 1%, 4%, 5%, 7.5%), or the 2.5% phosphatidylcholine content was maintained and the Lycoat RS780 content was adjusted (0.1%, 0.5%, 1%, 4%, 5%, 7.5%) – the difference was then subtracted from the maltodextrin. Additionally, complexes containing 1% RS780 + 1% phosphatidylcholine and 0.5% RS780 + 0.5% phosphatidylcholine were prepared. Finally, complexes containing only 2.5% of one additive (RS780 or phosphatidylcholine) served as control samples.

[0179] Complexes containing 2.5% Lycoat RS780 + varying amounts of phosphatidylcholine:

[0180] Composition with 2.5% Lycoat and 0.1% phosphatidylcholine (CC7A):

[0181] Component by weight %

[0182] Curcumin 10

[0183] Gamma-cyclodextrin 70

[0184] Phosphatidylcholine 0.1

[0185]

[0186] Modified strength (Lycoat RS780) 2.5

[0187] Maltodextrin 17.4

[0188]

[0189] Composition with 2.5% Lycoat and 0.5% Phosphatidylcholine (CC7B): Component Weight percentage wt% Curcumin 10

[0190] Gamma cyclodextrin 70 phosphatidylcholine 0.5

[0191] Modified strength (Lycoat RS780) 2.5

[0192] Maltodextrin 17

[0193]

[0194] Composition with 2.5% Lycoat and 1% Phosphatidylcholine (CC7C): Component Weight percentage wt% Curcumin 10

[0195] Gamma cyclodextrin 70 phosphatidylcholine 1

[0196] Modified strength (Lycoat RS780) 2.5

[0197] Maltodextrin 16.5

[0198]

[0199] Composition with 2.5% Lycoat and 4% Phosphatidylcholine (CC7D): Component Weight percentage wt% Curcumin 10

[0200] Gamma cyclodextrin 70 phosphatidylcholine 4

[0201] Modified strength (Lycoat RS780) 2.5

[0202] Maltodextrin 13.5

[0203]

[0204] Composition with 2.5% Lycoat and 5% Phosphatidylcholine (CC7E): Component Weight percentage wt% Curcumin 10

[0205] Gamma cyclodextrin 70 phosphatidylcholine 5

[0206] Modified strength (Lycoat RS780) 2.5

[0207] Maltodextrin 12.5

[0208]

[0209] Composition with 2.5% Lycoat and 7.5% phosphatidylcholine (CC7F): Component Weight percentage wt.%

[0210] Curcumin 10

[0211] Gamma-cyclodextrin 70

[0212] Phosphatidylcholine 7.5

[0213] Modified strength (Lycoat RS780) 2.5

[0214] Maltodextrin 10

[0215]

[0216] Complexes containing 2.5% phosphatidylcholine + varying amount of Lycoat RS780:

[0217] Composition containing 2.5% phosphatidylcholine and 0.1% Lycoat RS780 (CC8A):

[0218] Component by weight %

[0219] Curcumin 10

[0220] Gamma-cyclodextrin 70

[0221] Phosphatidylcholine 2.5

[0222] Modified strength (Lycoat RS780) 0.1

[0223] Maltodextrin 17.4

[0224]

[0225] Composition containing 2.5% phosphatidylcholine and 0.5% Lycoat RS780 (CC8B):

[0226] Component by weight %

[0227] Curcumin 10

[0228] Gamma-cyclodextrin 70

[0229] Phosphatidylcholine 2.5

[0230] Modified strength (Lycoat RS780) 0.5

[0231] Maltodextrin 17

[0232]

[0233] Composition containing 2.5% phosphatidylcholine and 1% Lycoat RS780 (CC8C):

[0234] Component by weight %

[0235] Curcumin 10

[0236] Gamma-cyclodextrin 70

[0237] Phosphatidylcholine 2.5

[0238] Modified strength (Lycoat RS780) 1

[0239] Maltodextrin 16.5

[0240]

[0241] Composition containing 2.5% phosphatidylcholine and 4% Lycoat RS780 (CC8D):

[0242] Component by weight %

[0243] Curcumin 10

[0244]

[0245] Gamma-cyclodextrin 70

[0246] Phosphatidylcholine 2.5

[0247] Modified strength (Lycoat RS780) 4

[0248] Maltodextrin 13.5

[0249]

[0250] Composition containing 2.5% phosphatidylcholine and 5% Lycoat RS780 (CC8E):

[0251] Component by weight %

[0252] Curcumin 10

[0253] Gamma-cyclodextrin 70

[0254] Phosphatidylcholine 2.5

[0255] Modified strength (Lycoat RS780) 5

[0256] Maltodextrin 12.5

[0257]

[0258] Composition containing 2.5% phosphatidylcholine and 7.5% Lycoat RS780 (CC8F):

[0259] Component by weight %

[0260] Curcumin 10

[0261] Gamma-cyclodextrin 70

[0262] Phosphatidylcholine 2.5

[0263] Modified strength (Lycoat RS780) 7.5

[0264] Maltodextrin 10

[0265]

[0266] Complexes containing identical proportions of phosphatidylcholine and Lycoat RS780 (0.5% and 1% respectively):

[0267] Composition containing 0.5% phosphatidylcholine and 0.5% Lycoat RS780 (CC9A):

[0268] Component by weight %

[0269] Curcumin 10

[0270] Gamma-cyclodextrin 70

[0271] Phosphatidylcholine 0.5

[0272] Modified strength (Lycoat RS780) 0.5

[0273] Maltodextrin 19

[0274]

[0275] Composition containing 1% phosphatidylcholine and 1% Lycoat RS780 (CC9B):

[0276] Component by weight %

[0277] Curcumin 10

[0278] Gamma-cyclodextrin 70

[0279]

[0280] Phosphatidylcholine 1

[0281] Modified strength (Lycoat RS780) 1

[0282] Maltodextrin 18

[0283]

[0284] Control complexes containing only one additive at 2.5% (phosphatidylcholine or Lycoat RS780):

[0285] Composition with 2.5% phosphatidylcholine and 0% Lycoat RS780 (CC10A):

[0286] Component by weight %

[0287] Curcumin 10

[0288] Gamma-cyclodextrin 70

[0289] Phosphatidylcholine 2.5

[0290] Modified strength (Lycoat RS780) 0

[0291] Maltodextrin 17.5

[0292]

[0293] Composition with 0% phosphatidylcholine and 2.5% Lycoat RS780 (CC10B):

[0294] Component by weight %

[0295] Curcumin 10

[0296] Gamma-cyclodextrin 70

[0297] Phosphatidylcholine 0

[0298] Modified strength (Lycoat RS780) 2.5

[0299] Maltodextrin 17.5

[0300]

[0301] To measure saturation solubility, samples containing 25 mg of curcumin were weighed precisely according to the procedure described in section 2.1 and dispersed in 100 ml of biorelevant buffer (FASSIF-V2, biorelevant: pH 6.5, buffer capacity 10 mmol / Δ pH / L containing 3 mM sodium taurocholate; 0.2 mM lecithin; 19.12 mM maleic acid; 34.8 mM sodium hydroxide; 68.62 mM sodium chloride, corresponding to physiological intestinal medium with respect to composition, pH, ion strength, and buffer capacity) and then incubated for 2 hours with gentle shaking. Afterward, the samples were filtered using a syringe filter, and the curcumin concentration of the filtrate was determined by HPLC. The experiments were performed using triplicates; the average values ​​are presented in tabular form.

[0302] For clarity, the values ​​for the complex containing gamma-cyclodextrin, each containing 2.5% of Lycoat RS780 and phosphatidylcholine (CC2A), are also included in the table: Complex Proportion Proportion PC Volume Saturation Solubility Saturation Solubility RS780 [%] [%] FASSIF- Curcumin in Curcumin in V2 [ml] FASSIF-V2 [pg / ml] FASSIF-V2 [%] CC7A 2.5 0.1 100 78.6 31.44

[0303] CC7B 2.5 0.5 100 137.4 54.96

[0304] CC7C 2.5 1 100 142.6 57.04

[0305] CC7D 2.5 4 100 118.7 47.48

[0306] CC7E 2.5 5 100 104.8 41.92

[0307] CC7F 2.5 7.5 100 81.2 32.48

[0308] CC8A 0.1 2.5 100 130.6 52.24

[0309] CC8B 0.5 2.5 100 160.4 64.16

[0310] CC8C 1 2.5 100 183.7 73.48

[0311] CC8D 4 2.5 100 109.2 43.68

[0312] CC8E 5 2.5 100 89.4 35.76

[0313] CC8F 7.5 2.5 100 72.2 28.88

[0314] CC9A 0.5 0.5 100 120.3 48.12

[0315] CC9B 1 1 100 136.7 54.68

[0316] CC2A 2.5 2.5 100 158.2 63.28

[0317] CC10A 0 2.5 100 65.2 26.08

[0318] CC10B 2.5 0 100 52.3 20.92

[0319] Native GCD gamma none 100 54.6 21.84 Curcumin - - 100 1.23 0.492

[0320]

[0321] 3. Active ingredient formulations containing silybin

[0322] Ingredients: Silybin (98%, Fengrui Biotechnology Co., Ltd.), alpha-cyclodextrin (CAVAMAX W6, Wacker Chemie), beta-cyclodextrin (CAVAMAX W7, Wacker Chemie), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (96%, LIPOID H100, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), modified starches (see 1. Characterization of starches).

[0323] 3.1 Influence of the modified strength

[0324] To estimate the optimal starch type, powdered silybin complexes with the following final composition were prepared: Component Weight percentage wt.%

[0325] Silybin 32

[0326] Gamma-cyclodextrin 50

[0327] Phosphatidylcholine 2

[0328] Modified Strength 1

[0329] Maltodextrin 15

[0330]

[0331] First, 75g of gamma-cyclodextrin (CAVAMAX W8) and 48g of silybin were stirred into 850ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 7000 rpm for 1-2 minutes and then dispersed for a further 30 minutes at 5000 rpm to allow complex formation. Following this, 1.5g of modified starch (HC100, NC2230, RS780, T301, FTTS, P87, PVA70, FTM) and 3g of phosphatidylcholine (Lipoid H100) were homogeneously dispersed while stirring.

[0332] The solution was then homogenized using a high-pressure homogenizer (GEA, PandaPlus 1000) at 300 bar in 2 cycles and subsequently weighed.

[0333] Subsequently, 22.5g of maltodextrin (GLUCIDEX 19) - corrected for the yield (yield in g / theoretical yield in g x 22.5g) - were weighed out and dissolved in the milled suspension by stirring.

[0334] The suspensions were last dried using a laboratory spray dryer (Büchi B-290, 5ml / min flow, inlet temperature 140°C, 600l / h spray gas, 35 m3 / h aspirator).

[0335] For reference, a native gamma-cyclodextrin / silybin complex (native GCD) was also prepared, initially following the same procedure: 75 g of gamma-cyclodextrin (CAVAMAX W8) and 48 g of silybin were stirred into 850 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 7000 rpm for 1–2 minutes and then dispersed for complex formation for a further 30 minutes at 5000 rpm. Drying was then carried out using a spray dryer with the spray parameters mentioned above.

[0336] The powdered complexes were characterized with respect to loss on drying (halogen dryer), particle size in solution (D50 value, laser diffraction), and silybin content (HPLC). A Mastersizer 3000 (Malvern Panalytical) with a Hydro MV wet dispersion element was used to measure the particle size in solution. For this purpose, 25 mg of precisely weighed sample was dispersed in 120 ml of water with a drop of Igepal solution for 10 minutes using gentle ultrasound to separate the particles, which were then measured (evaluation using Mie theory).

[0337] Complex starch type Used Loss on drying Silybin content D50 value [pm]

[0338] Starch [%] [wt.%]

[0339] SB1A OSA HC100 3.3 31.7 4.821 SB1B OSA NC2230 6.2 32.1 16.733 SB2A HP RS780 4.1 31.3 3.216 SB2B HP T301 6.8 32.6 12.429 SB2C HP FTTS 6.2 31.8 23.961 SB3A HDP P87 6.7 32.2 25.596 SB3B HDP PVA70 7.8 31.2 34.821 SB4A AS FTM 5.9 31.8 18.946 Native GCD none none 5.6 38.7 28.393 Silybin - - 0.92 98.7 18.767

[0340]

[0341] The in vitro release was then investigated according to the specifications of the pharmacopoeia (Ph. Eur. 11.0 Chapter 2.9.3. Release of solid dosage forms). For this purpose, the USP Apparatus II (paddle / leaf stirrer) was selected, with a rotation speed of 50 rpm, a volume of 500 ml, and a temperature of 37°C. A 0.05 M phosphate buffer (pH 6.8) + 0.1% SDS was chosen as the medium.

[0342] Samples containing 100 mg of silybin were weighed precisely, corresponding to a target concentration of 200 pg / ml silybin. After the medium was brought to the target temperature and the samples were placed in the vessels, samples were drawn after 15, 30, 60, and 120 minutes. The samples were filtered using a syringe filter, and the silybin concentration was determined by HPLC. The withdrawn sample volume was immediately replaced with fresh, pre-tempered medium. The experiments were performed using triplicates, and the mean release values ​​(Q in %) are presented in tabular form.

[0343] Complex Strength Type Used Q by Q by Q by Q by Strength 15 min [%] 30 min [%] 60 min [%] 120 min [%] SB1A OSA HC100 11.2 13.91 15.63 16.12 SB1B OSA NC2230 3.21 4.56 6.72 8.23

[0344]

[0345] SB2A HP RS780 21.53 26.78 41.29 43.64 SB2B HP T301 9.89 13.92 16.93 18.93 SB2C HP FTTS 3.91 5.82 7.92 9.48 SB3A HDP P87 5.62 6.82 8.92 10.32 SB3B HDP PVA70 2.23 3.28 4.89 5.31 SB4A AS FTM 4.29 5.21 7.83 8.79 Native GCD none none 8.34 12.89 13.44 13.89 Silybin - - 1.53 1.89 2.15 2.33

[0346]

[0347] Only low-viscosity hydroxypropyl starch in combination with phosphatidylcholine achieves a significant increase in saturation solubility and release compared to a native gamma cyclodextrin / silybin complex.

[0348] 3.2 Influence of the cyclodextrin type

[0349] To investigate the influence of the cyclodextrin type, complexes were prepared according to the procedure from 3.1 using the best modified starch (Lycoat RS780), which, however, contained alpha- or beta-cyclodextrin instead of gamma-cyclodextrin.

[0350] Composition with alpha-cyclodextrin (SB5A):

[0351] Component by weight %

[0352] Silybin 32

[0353] Alpha-Cyclodextrin 50

[0354] Phosphatidylcholine 2

[0355] Modified strength (Lycoat RS780) 1

[0356] Maltodextrin 15

[0357]

[0358] Composition with beta-cyclodextrin (SB6A):

[0359] Component by weight %

[0360] Silybin 32

[0361] Beta-cyclodextrin 50

[0362] Phosphatidylcholine 2

[0363] Modified strength (Lycoat RS780) 1

[0364] Maltodextrin 15

[0365]

[0366] For reference, native alpha / beta-cyclodextrin:silybin complexes (native ACD and native BCD) were also prepared using the same procedure: 75 g of alpha-cyclodextrin (CAVAMAX W6) or 75 g of beta-cyclodextrin (CAVAMAX W7) and 48 g of silybin were stirred into 850 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 7000 rpm for 1-2 minutes and then dispersed for a further 30 minutes at 5000 rpm to facilitate complex formation. Drying was then carried out using a spray dryer with the spray parameters mentioned above.

[0367] To measure saturation solubility, samples containing 50 mg of silybin were precisely weighed and dispersed in 100 ml of 0.05 M phosphate buffer, pH 6.8 + 0.1% SDS, and then incubated for 2 h with gentle shaking. The samples were then filtered using a syringe filter, and the silybin concentration of the filtrate was determined by HPLC. The experiments were performed using triplicates, and the mean values ​​are presented in tabular form.

[0368] The experiments were also performed with the best complex of 3.3.1 (SB2A with RS780) and native silybin / gamma cyclodextrin complex (native GCD):

[0369] Complex CD Used Volume Saturation Solubility Saturation Solubility Strength FASSIF- Silybin in PBS pH Silybin in PBS pH V2 [ml] 6.8 +0.1% SDS 6.8 +0.1% SDS [%]

[0370] [pg / ml]

[0371] SB5A alpha RS780 100 22.55 4.51

[0372] Native ACD alpha not 100 19.45 3.89

[0373] SB6A beta RS780 100 33.9 6.78

[0374] Native BCD beta no 100 29.1 5.82

[0375] SB2A gamma RS780 100 189.55 37.91

[0376] Native GCD gamma not 100 44.55 8.91

[0377] Silybin - - 100 77 1.54

[0378]

[0379] Only with gamma-cyclodextrin was a significant increase in saturation solubility achieved—both relatively compared to the respective native complex and absolutely.

[0380] 4. Active ingredient formulation with quercetin

[0381] Ingredients: Quercetin dihydrate (95%, Shaanxi Jia He Phytochem Co., Ltd.), alpha-cyclodextrin (CAVAMAX W6, Wacker Chemie), beta-cyclodextrin (CAVAMAX W7, Wacker Chemie), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (96%, LIPOIDH100, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), ammonia solution (9% aqueous ammonia, generic), HCl (fuming 32%, generic), Lycoat RS780 (Roquette)

[0382] 4.7 Complex manufacturing

[0383] To estimate the optimal cyclodextrin type, powdered quercetin complexes with the following final composition were prepared:

[0384] Component by weight [wt.%]

[0385] Quercetin Dihydrate 16

[0386] Cyclodextrin (alpha, beta or gamma) 60

[0387] Phosphatidylcholine / Lipoid H100 3

[0388] Lycoat RS780 3

[0389] Maltodextrin / Glucidex DE 19 18

[0390]

[0391] First, 75 g of cyclodextrin (CAVAMAX W6, W7, or W8) and 20 g of quercetin dihydrate were dispersed in 875 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 5000 rpm. The pH was then adjusted to 9 with aqueous ammonia solution. To initiate complex formation, the suspension was dispersed for a further 30 minutes at 5000 rpm, and the pH was subsequently neutralized by adding HCl solution while stirring gently (final pH 2.5–3.5). Following this, 3.75 g of modified starch (RS780) and 3.75 g of phosphatidylcholine (Lipoid H100) were homogeneously dispersed while stirring.

[0392] The suspensions were then milled in a circular motion for 30 minutes using a ball mill (WAB, DYNO-MILL Research Lab, 70% filling with 0.3-0.4 mm zirconia beads, 8 m / s tip speed) and subsequently weighed. Then, 22.5 g of maltodextrin (GLUCIDEX 19) – corrected for the yield (yield in g / theoretical yield in g x 22.5 g) – were weighed out and dissolved in the milled suspension with stirring. Finally, the suspensions were dried using a laboratory spray dryer (Büchi B-290, 5 ml / min flow, inlet temperature 145°C, 800 l / h spray gas, 35 m³ / h aspirator).

[0393] For reference, native cyclodextrin / quercetin complexes (native ACD, native BCD, native GCD) were also prepared, initially following the same procedure: 75 g of cyclodextrin (CAVAMAX W6, W7, or W8) and 20 g of quercetin dihydrate were dispersed in 875 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 5000 rpm and then adjusted to a pH of 9 with aqueous ammonia solution. For complex formation, the suspension was dispersed for a further 30 min at 5000 rpm, and the pH of the suspension was subsequently neutralized by adding HCl solution with gentle stirring (final pH 2.5–3.5) and then dried using a spray dryer with the same spray parameters.

[0394] For control purposes, complexes containing gamma-cyclodextrin with either only 3% RS780 or only 3% Lipoid H100 as an additive were also produced using the manufacturing process mentioned above:

[0395] Composition with 3% RS780 (Q3B):

[0396] Component by weight [wt.%]

[0397] Quercetin Dihydrate 16

[0398] Gamma Cyclodextrin 60

[0399] Phosphatidylcholine / Lipoid H100 0

[0400] Lycoat RS780 3

[0401] Maltodextrin / Glucidex DE 19 21

[0402]

[0403] Composition with 3% Lipoid H100 (Q3C):

[0404] Component by weight [wt.%]

[0405] Quercetin Dihydrate 16

[0406] Gamma Cyclodextrin 60

[0407] Phosphatidylcholine / Lipoid H100 3

[0408] Lycoat RS780 0

[0409] Maltodextrin / Glucidex DE 19 21

[0410]

[0411] 4.2 Saturation solubility of the complexes

[0412] To measure saturation solubility, samples containing 75 mg of quercetin dihydrate were precisely weighed and dispersed in 100 ml of biorelevant buffer (FASSIF-V2, biorelevant: pH 6.5, buffer capacity 10 mmol / Δ pH / L containing 3 mM sodium taurocholate; 0.2 mM lecithin; 19.12 mM maleic acid; 34.8 mM sodium hydroxide; 68.62 mM sodium chloride, corresponding to physiological intestinal fluid in terms of composition, pH, ion strength, and buffer capacity) and then incubated for 2 h with gentle shaking. The samples were then filtered using a syringe filter, and the quercetin concentration of the filtrate was determined by HPLC (calculated as the dihydrate). The experiments were performed using triplicates, and the mean values ​​are presented in tabular form. Pure quercetin dihydrate was included as a control.

[0413] Complex CD Used PC Volume Saturation Solubility Saturation Solubility Strength FASSIF-hity Quercetin hity Quercetin V2 [ml] in FASSIF-V2 in FASSIF-V2

[0414] [pg / ml] [%]

[0415] Q1A alpha RS780 Yes 100 28.63 3.82

[0416] Native ACD alpha no No 100 23.45 3.13

[0417] Q2A beta RS780 Yes 100 100.91 13.45 Native BCD beta none No 100 88.52 11.80 Q3A gamma RS780 Yes 100 441.10 58.81 Q3B gamma RS780 No 100 45.63 6.08

[0418] Q3C gamma none Yes 100 77.94 10.39 Native GCD gamma none No 100 40.66 5.42 Quercetin - - - 100 14.40 1.92

[0419]

[0420] Although the native complex containing beta-cyclodextrin generally has a higher solubility in FASSIF-V2, the inventive formulation only significantly increases the solubility of gamma-cyclodextrin compared to the native complex and in absolute terms compared to all formulations tested.

[0421] 5. Active ingredient formulations containing boswellic acids

[0422] Material: Boswellia Serrata extract (85% boswellic acids, determined by titration, Shaanxi Jia He Phytochem Co., Ltd.), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (96%, LIPOID H100, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), Lycoat RS780 (Roquette).

[0423] 5.1 Complex manufacturing

[0424] To determine the influence of the weight fraction of the modified starch and the phosphatidylcholine, complexes with the two additives starch (Lycoat RS780) and phosphatidylcholine (Lipoid H100) as well as gamma-cyclodextrin were produced, which, however, contained different weight fractions of the two additives.

[0425] Composition containing only 1.5% RS780 (BS1A):

[0426] Component by weight %

[0427]

[0428] Boswellia Serrata Extract (85% 27 Boswellic Acids)

[0429] Gamma Cyclodextrin 53 Phosphatidylcholine / Lipoid H100 0

[0430] Lycoat RS780 1.5 Maltodextrin / Glucidex DE 19 18.5

[0431]

[0432] Composition with only 1.5% Lipoid H100 (BS1B):

[0433] Component by weight % Boswellia Serrata extract (85% 27 boswellic acids)

[0434] Gamma Cyclodextrin 53 Phosphatidylcholine / Lipoid H100 1.5

[0435] Lycoat RS780 0 Maltodextrin / Glucidex DE 19 18.5

[0436]

[0437] Composition containing 0.5% each of RS780 and Lipoid H100 (BS2A):

[0438] Component by weight % Boswellia Serrata extract (85% 27 boswellic acids)

[0439] Gamma Cyclodextrin 53 Phosphatidylcholine / Lipoid H100 0.5

[0440] Lycoat RS780 0.5 Maltodextrin / Glucidex DE 19 19

[0441]

[0442] Composition containing 1.5% each of RS780 and Lipoid H100 (BS2B):

[0443] Component by weight % Boswellia Serrata extract (85% 27 boswellic acids)

[0444] Gamma Cyclodextrin 53 Phosphatidylcholine / Lipoid H100 1.5

[0445] Lycoat RS780 1.5 Maltodextrin / Glucidex DE 19 17

[0446]

[0447] Composition containing 3% each of RS780 and Lipoid H100 (BS2C):

[0448] Component by weight %

[0449]

[0450] Boswellia Serrata Extract (85% 27

[0451] Boswellic acids)

[0452] Gamma Cyclodextrin 53

[0453] Phosphatidylcholine / Lipoid H100 3

[0454] Lycoat RS780 3

[0455] Maltodextrin / Glucidex DE 19 14

[0456]

[0457] Composition with 1.5% RS780 and 3% Lipoid H100 (BS3A):

[0458] Component by weight %

[0459] Boswellia Serrata Extract (85% 27

[0460] Boswellic acids)

[0461] Gamma Cyclodextrin 53

[0462] Phosphatidylcholine / Lipoid H100 3

[0463] Lycoat RS780 1.5

[0464] Maltodextrin / Glucidex DE 19 15.5

[0465]

[0466] Composition with 3% RS780 and 1.5% Lipoid H100 (BS3B):

[0467] Component by weight %

[0468] Boswellia Serrata Extract (85% 27

[0469] Boswellic acids)

[0470] Gamma Cyclodextrin 53

[0471] Phosphatidylcholine / Lipoid H100 1.5

[0472] Lycoat RS780 3

[0473] Maltodextrin / Glucidex DE 19 15.5

[0474]

[0475] For this purpose, 79.5 g of gamma-cyclodextrin (CAVAMAX W8) and 40.5 g of Boswellia serrata extract were first stirred into 850 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 6000 rpm for 1-2 minutes and then dispersed for a further 30 minutes at 4000 rpm to form the complex. Following this, the calculated amounts of modified starch (RS780) and phosphatidylcholine (Lipoid H100), depending on the composition of the complex, were homogeneously dispersed while stirring.

[0476] The solution was then homogenized using a high-pressure homogenizer (GEA, PandaPlus 1000) at 400 bar in 3 cycles and subsequently weighed. The required amount of maltodextrin (GLUCIDEX 19), adjusted for yield depending on the composition of the complex, was then weighed out and dissolved in the milled suspension by stirring.

[0477] The suspensions were last dried using a laboratory spray dryer (Büchi B-290, 5ml / min flow, inlet temperature 140°C, 600l / h spray gas, 35 m3 / h aspirator).

[0478] For reference, a native gamma-cyclodextrin / Boswellia complex (native GCD) was also prepared, initially following the same procedure: 79.5 g of gamma-cyclodextrin (CAVAMAX W8) and 40.5 g of Boswellia serrata extract were stirred into 850 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 6000 rpm for 1–2 minutes and then dispersed for a further 30 minutes at 4000 rpm to form the complex. Drying was then carried out using a spray dryer with the spray parameters mentioned above.

[0479] 5.2 In-vitro release of the formulations

[0480] Subsequently, the in vitro release was investigated according to the specifications of the pharmacopoeia (Ph. Eur. 11.0 Chapter 2.9.3. Release of solid dosage forms). For this purpose, the USP Apparatus II (paddle / leaf stirrer) was selected, the rotation speed was 50 rpm, V = 500 ml Fassif-V2 medium, T = 37°C.

[0481] The content of acetyl-11-keto-β-boswellic acid (AKBA) and 11-keto-β-boswellic acid (KBA) was determined for each of the prepared complexes; these two boswellic acids are used as analytes for the release experiments.

[0482] Samples containing 12.5 mg boswellic acids (AKBA + KBA) were precisely weighed, corresponding to a target concentration of 25 pg / ml AKBA+KBA. After the medium was brought to the target temperature and the samples were placed in the vessels, samples were drawn after 15, 30, 60, and 120 minutes. The samples were filtered using a syringe filter, and the boswellic acid concentration was determined by HPLC. The withdrawn sample volume was immediately replaced with fresh, pre-tempered FASSIF-V2 medium. The experiments were performed using triplicates, and the mean release values ​​(Q in %) are shown in the table. Complex Proportion Proportion PC Q after Q after Q after Q after RS780 [%] 15 min [%] 30 min [%] 60 min [%] 120 min [%] [%]

[0483] BS1A 1.5 0 11.72 13.41 16.89 16.42 BS1B 0 1.5 15.94 16.38 17.02 17.84 BS2A 0.5 0.5 24.86 28.28 26.95 23.43 BS2B 1.5 1.5 33.51 36.89 38.76 39.44 BS2C 3 3 21.57 26.93 27.45 28.82 BS3A 1.5 3 41.42 45.89 47.32 46.93 BS3B 3 1.5 24.27 23.44 23.78 25.96 Native GCD none none 9.03 12.42 14.86 16.80 Boswellia 0.61 0.93 1.47 2.01 Serrata

[0484] extract

[0485]

[0486] 6. Active ingredient formulations containing berberine

[0487] Material: Berberine HCl (97.9% Thermo Fisher Scientific), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (96%, LIPOID H100, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), Lycoat RS780 (Roquette).

[0488] 6.1 Complex manufacturing

[0489] The following complex containing berberine HCl was prepared (BB1A):

[0490] Component by weight %

[0491] Berberine HCl 18

[0492] Gamma Cyclodextrin 62

[0493] Phosphatidylcholine / Lipoid H100 1.75

[0494] Lycoat RS780 1.75

[0495] Maltodextrin / Glucidex DE 19 16.5

[0496]

[0497] First, 62 g of gamma-cyclodextrin (CAVAMAX W8) and 18 g of berberine HCl were stirred into 900 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 10,000 rpm for 1–2 minutes. The mixture was then dispersed for a further 30 minutes at 8,000 rpm to allow for complex formation. Next, 1.75 g each of modified starch (RS780) and phosphatidylcholine (Lipoid H100) were homogeneously dispersed while stirring. Finally, the solution was homogenized in one cycle using a high-pressure homogenizer (GEA, PandaPlus 1000) at 500 bar and subsequently weighed.

[0498] Subsequently, 16 g of maltodextrin (GLUCIDEX 19) – corrected for yield – were weighed out and dissolved in the milled suspension by stirring.

[0499] The suspensions were last dried using a laboratory spray dryer (Büchi B-290, 5ml / min flow, inlet temperature 140°C, 800l / h spray gas, 35 m3 / h aspirator).

[0500] For reference, a native gamma-cyclodextrin / berberine complex (native GCD) was also prepared, initially following the same procedure: 62 g of gamma-cyclodextrin (CAVAMAX W8) and 18 g of berberine HCl were stirred into 900 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 10,000 rpm for 1–2 minutes and then dispersed for complex formation for a further 30 minutes at 8,000 rpm. Drying was then carried out using a spray dryer with the spray parameters mentioned above.

[0501] 6.2 Saturation solubility of the complexes

[0502] To measure saturation solubility, samples containing 20 mg berberine HCl were precisely weighed and dispersed in 2 ml of 0.05 M phosphate buffer, pH 6.8, and then incubated for 2 h with gentle shaking. The samples were then filtered using a syringe filter, and the berberine concentration of the filtrate was determined by HPLC. All assays were performed using triplicates; the mean values ​​are presented in tabular form.

[0503] The experiments were performed with BB1A, the native berberine / gamma-cyclodextrin complex, and pure berberine HCl.

[0504] Complex CD Additive Volume Saturation Solubility Saturation Solubility PBS pH Berberine in PBS pH Berberine in PBS pH 6.8 [ml] 6.8 [mg / ml] 6.8 [%]

[0505] BB1A gamma 1.75% RS780 2 8.69 86.9

[0506] +1.75% H100

[0507] Native GCD gamma no 2 2.86 28.6

[0508] Berberine - - 2 1.38 13.8

[0509] HCl

[0510]

[0511] The inventive formulation enabled a significant increase in saturation solubility compared to the pure active ingredient and the gamma-cyclodextrin complex.

[0512] 1. Active ingredient formulations with ubiquinone-10 / coenzyme Q10

[0513] Material: Ubiquinone-10 / Coenzyme Q10 (99%, Shaanxi Jia He Phytochem Co., Ltd), gamma-cyclodextrin (CAVAMAX W8, Wacker Chemie), phosphatidylcholine (85%, LIPOID H85, Lipoid), maltodextrin (GLUCIDEX DE 19, Roquette), modified starches (see 1. Characterization of starches).

[0514] 3.1 Influence of the modified strength

[0515] Powdered ubiquinone-10 complexes with the following final composition were prepared to estimate the optimal starch type:

[0516] Component by weight %

[0517] Ubiquinone-10 20

[0518] Gamma-cyclodextrin 60

[0519] Phosphatidylcholine 1.5

[0520] Modified strength 1.5

[0521] Maltodextrin 17

[0522]

[0523] First, 90 g of gamma-cyclodextrin (CAVAMAX W8) and 30 g of ubiquinone were stirred into 850 ml of distilled water using a high-shear homogenizer (IKA Ultra Turrax T 18) at 10,000 rpm for 5 minutes and then dispersed for a further 30 minutes at 6,000 rpm to allow complex formation. Following this, 2.25 g of modified starch (HC100, NC2230, RS780, RS720, T301) and 2.25 g of phosphatidylcholine (Lipoid H85) were homogeneously dispersed while stirring.

[0524] The suspensions were then milled in a circular motion for 45 minutes using a ball mill (WAB, DYNO-MILL Research Lab, 75% filling with 0.3-0.4 mm zirconia beads, 8 m / s tip speed) and subsequently weighed. Then, 25.5 g of maltodextrin (GLUCIDEX 19) – corrected for the yield (yield in g / theoretical yield in g x 25.5 g) – were weighed out and dissolved in the milled suspension with stirring. Finally, the suspensions were dried using a Millrock STELLAR Laboratory Freeze Dryer (-40 °C freezing temperature, 0.1 mbar chamber pressure, shelf drying at -20 °C primary / +20 °C secondary, 24 h total drying time).

[0525] For reference, a native gamma-cyclodextrin / ubiquinone-10 complex (native GCD) and a native gamma-cyclodextrin / ubiquinone-10 / phospholipid complex were also prepared, initially following the same procedure: 90g gamma-cyclodextrin (CAVAMAX W8) and 30g ubiquinone-10 and optionally 2.25g phosphatidylcholine (lipid H85) were stirred in 850ml distilled water using a high shear homogenizer (IKA Ultra Turrax T 18) at 10000 rpm for 5 minutes and then dispersed for complex formation for a further 30 minutes at 6000 rpm. The suspensions were then milled in a circular motion for 45 minutes using a ball mill (WAB, DYNO-MILL Research Lab, 75% filling with 0.3-0, 4mm zirconia beads, 8m / s tip speed) and subsequently freeze-dried under the parameters specified above.

[0526] The powdered complexes were characterized with respect to ubiquinone-10 content (HPLC).

[0527] Complex Starch Type Used Ubicholine-10 Content [wt. starch phospholipid %]

[0528] UB1A OSA HC100 Lipoid H85 18.3

[0529] UB1B OSA NC2230 Lipoid H85 19.2

[0530] UB2A HP RS780 Lipoid H85 19.5

[0531] UB2B HP RS720 Lipoid H85 19.7

[0532] UB2C HP T301 Lipoid H85 19.3

[0533] UB2D - - Lipoid H85 24.2

[0534] Native GCD - - - 24.6

[0535] Ubiquinone-10 - - 99.3

[0536]

[0537] Subsequently, the in vitro release was investigated according to the specifications of the pharmacopoeia (Ph. Eur. 11.0 Chapter 2.9.3. Release of solid dosage forms). For this purpose, the USP Apparatus II (paddle / leaf stirrer) was selected, the rotation speed was 75 rpm, V = 500 ml Fassif-V2 medium, T = 37°C.

[0538] Samples containing 125 mg of ubiquinone-10 were precisely weighed, corresponding to a target concentration of 250 pg / ml ubiquinone-10. After the medium was brought to the target temperature and the samples were placed in the vessels, samples were drawn after 15, 30, 60, and 120 minutes. The samples were filtered using a syringe filter, and the ubiquinone-10 concentration was determined by HPLC. The withdrawn sample volume was immediately replaced with fresh, pre-tempered medium. The experiments were performed using triplicates, and the mean release values ​​(Q in %) are presented in tabular form.

[0539] Complex Strength Type Used Q by Q by Q by Q by Strength 15 min [%] 30 min [%] 60 min [%] 120 min [%] UB1A OSA HC100 4.59 6.31 7.63 8.21

[0540] UB1B OSA NC2230 2.27 3.74 4.92 6.83

[0541] UB2A HP RS780 9.54 13.10 14.38 16.82

[0542] UB2B HP RS720 8.72 13.27 15.45 17.23

[0543] UB2C HP T301 6.62 7.33 9.82 11.52

[0544] UB2D - - 3.28 5.82 6.42 7.83

[0545] Native GCD none none 1.95 2.51 2.77 2.98 Ubiquinone - - 0.02 0.05 0.13 0.32

[0546] 10

[0547]

[0548] To measure saturation solubility, samples containing 50 mg of ubiquinone-10 were precisely weighed and dispersed in 100 ml of FASSIF-V2, then incubated for 2 h at 37°C with gentle shaking. The samples were then filtered using a syringe filter, and the ubiquinone-10 concentration of the filtrate was determined by HPLC. All experiments were performed using triplicates; the mean values ​​are presented in tabular form.

[0549] Complex Starch Type Volume Used Saturation Solubility Saturation Solubility Starch FASSIF- Ubiquinone-10 in Ubiquinone-10 in V2 [ml] FASSIF-V2 [pg / ml] FASSIF-V2 [%] UB1A OSA HC100 100 27.15 5.43

[0550] UB1B OSA NC2230 100 21.93 4.38

[0551] UB2A HP RS780 100 79.45 15.89

[0552] UB2B HP RS720 100 67.05 13.41

[0553] UB2C HP T301 100 44.40 8.88

[0554] UB2D - - 100 28.65 5.73

[0555] Native GCD none none 100 11.71 2.34

[0556] Ubiquinone- - - 0.63 0.12

[0557] 10

[0558]

Claims

Claims 1. Composition comprising at least one cyclodextrin complex, wherein at least one active ingredient is associated with gamma-cyclodextrin, the cyclodextrin complex having a coating comprising hydroxypropyl starch and phosphatidylcholine, wherein the weight fraction of the active ingredient is 5-50 wt.%, preferably 10-40 wt.%. the weight fraction of gamma-cyclodextrin is 35-90 wt.%, preferably 50-85 wt.%, the weight fraction of hydroxypropyl starch is 0.1-10 wt.%, preferably 0.5-7.55 wt.%, further preferably 0.75-4 wt.%, particularly preferably 1-3.5 wt.%, and the weight fraction of phosphatidylcholine is 0.1-10 wt.%, preferably 0.5-7.5 wt.%, further preferably 1-4.5 wt.%, particularly preferably 1.5-4 wt.%, each based on the total mass of the coated complex.

2. Composition according to claim 1, wherein the hydroxypropyl starch has a viscosity of not more than 1800 mPas, preferably < 500 mPas, more preferably < 250 mPas, in particular < 100 mPas, especially preferably < 75 mPas, most preferably < 50 mPas, as determined by rotational viscometry, and / or wherein the hydroxypropyl starch has a degree of substitution of 0.1-15%, preferably 0.5-10%, more preferably 2-7%, as determined by nuclear magnetic resonance spectroscopy.

3. Composition according to claim 1 or 2, wherein the active ingredient has a molecular weight of 150-2000 g / mol and / or a water solubility of < 10 mg / ml, preferably < 1 mg / ml.

4. Composition according to any of the preceding claims, wherein the composition is in solid form, in particular as a powder or granules.

5. Composition according to any one of the preceding claims, wherein the total proportion of the active ingredient and the gamma-cyclodextrin together is 85-99 wt.%, preferably 90-98.5 wt.%, particularly preferably 93-98 wt.%, based on the total mass of the coated complex.

6. Composition according to any one of the preceding claims, wherein the total proportion of the phosphatidylcholine and the hydroxypropyl starch together is 0.5-15 wt.%, preferably 1-10 wt.%, further preferably 1.5-8.5 wt.%, particularly preferably 2-7 wt.%, based on the total mass of the coated complex.

7. Composition according to any one of the preceding claims, wherein the composition further comprises one or more saccharides, preferably in an amount of 5-50 wt.%, preferably 10-40 wt.%, particularly preferably 12.5-35 wt.%, most preferably 15-30 wt.%, based on the total mass of the coated complex, optional, wherein one or more saccharides are selected from the group comprising maltodextrin, glucose, sucrose, fructose, maltose, lactose, galactose, trehalose, mannose and combinations thereof.

8. Composition according to any of the preceding claims, wherein the coated cyclodextrin complexes are in the form of agglomerates of several coated cyclodextrin complexes.

9. Composition according to any of the preceding claims, wherein the composition is a composition for oral administration, in particular a tablet, capsule, chewable, orodispersible or effervescent tablet, a granule, powder, a solution for oral administration, a coated tablet, a sublingual / buccal tablet or an orodispersible film.

10. Composition according to any of the preceding claims, wherein the composition is a pharmaceutical or nutraceutical composition or a foodstuff.

11. Method for producing a composition according to any one of claims 1-10, comprising the steps: a) Dispersing gamma-cyclodextrin and at least one active ingredient in water while stirring to associate the active ingredient with the gamma-cyclodextrin, b) Coating the cyclodextrin complex formed in step (a) by adding hydroxypropyl starch and phosphatidylcholine while stirring and homogenizing to obtain a suspension of coated cyclodextrin complexes in water, and c) optionally drying the suspension obtained in step (b), in particular by spray drying.

12. The method of claim 11, wherein step (a) further comprises adjusting the pH to promote complexation of the active ingredient with gamma-cyclodextrin.

13. Method according to claim 11 or 12, wherein the homogenization in step (b) is carried out by means of high-pressure homogenization, ultrasonic homogenization or grinding, for example ball milling.

14. Method according to one of claims 11-13, wherein one or more saccharides are further added to the suspension of coated cyclodextrin complexes after step (b).

15. Method according to one of claims 11-14, wherein phosphatidylcholine is added in the form of a phospholipid mixture comprising at least 40 wt.%, preferably at least 80 wt.%, more preferably at least 90 wt.% phosphatidylcholine.